THYROCARE

- Thyrocare Technologies Limited has approved the allotment of 1,94,289 equity shares of ₹10 each pursuant to the Thyrocare Employee Stock Option Scheme (ESOS). - The allotment includes 1,29,526 equity shares pursuant to bonus adjustment. - Post-allotment, the paid-up equity share capital of the company increased from ₹159,16,53,150 to ₹159,35,96,040.

- Dr. Preet Kaur resigned as Chief Scientific Officer and Senior Management Personnel of Thyrocare Technologies Limited. - Resignation effective from November 06, 2026, to pursue an external career opportunity. - The company is in the process of identifying a suitable replacement.

Current scenario - Delivered consolidated revenue growth of 25% YoY in Q2 FY27, maintaining strong growth momentum. - Pathology business grew 27% YoY, driven by sustained investments in service levels, quality, and franchisee network expansion. - Active franchisee base reached a record 12,911 with the highest ever quarterly additions during the quarter. - Initiated the process for shareholders' approval to disinvest the radiology business (Nueclear Healthcare Limited - NHL) to Trovera for INR141 crores to focus on the higher-margin pathology business. Changes in trends - Specialty diagnostics (allergy and genomics) commercially launched and scaling up, currently contributing around 4% of pathology revenue. - Stepped into the consumer products business with the launch of the Thyrocare Pregnancy Test Kit bundled with a discounted Beta hCG blood test. Management Guidance & Outlook - Revenue growth guidance upgraded from mid-to-high teens to early 20s for the current financial year. - EBITDA margin expected to be maintained around 31% to 31.5% while funding growth and marketing investments. - Specialty segment targeted to reach 10% to 15% of revenue over a 3 to 5-year horizon. - Aims to continue adding 1,500 to 2,000 franchisees annually, reaching 20,000 to 25,000 franchisees in 5 years. Capex - Incurred INR30 crores of capex in H1 FY27 toward new lab expansions (5 new labs added in Q2) and volume capacity support, with similar levels expected in H2.